pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Antisense Oligonucleotide (ASO) · news · pharmadog
← back to Antisense Oligonucleotide (ASO)
News · Antisense Oligonucleotide (ASO)
61
stories
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 28, 26
‘Worse than expected’ Wainua data muddies water for TTR silencers
biospace
Aug 28, 26
AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond
fiercebiotech
Aug 24, 26
FDA extends review of Capricor cell therapy; Pain drug startup to go public
biopharma dive
Aug 17, 26
Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
fiercebiotech
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
Aug 12, 26
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
Aug 10, 26
Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
biospace
Aug 7, 26
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
Aug 3, 26
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
Jul 31, 26
Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
endpoints
Jul 30, 26
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
Jul 29, 26
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
Jul 28, 26
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
Jul 27, 26
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
fiercebiotech
Jul 27, 26
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 22, 26
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
fiercebiotech
Jul 22, 26
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
biospace
Jul 20, 26
Genetic medicine luminaries launch new center for personalized therapies
fiercebiotech
Jul 9, 26
Roche scraps two Ionis-partnered Huntington’s drugs
biopharma dive
Jul 9, 26
Updated: AstraZeneca sinks on unexpected heart drug trial failure
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 18, 26
Kardigan extends biotech’s streak of big IPOs with $400M haul
biopharma dive
Jun 11, 26
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
biopharma dive
Jun 10, 26
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
endpoints
Jun 4, 26
STAT+: AI titans push Congress for DNA safeguards
stat
May 28, 26
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
biopharma dive
May 14, 26
Biogen pushing tau drug forward despite Alzheimer’s study failure
biopharma dive
May 8, 26
First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC
onclive
← prev
page 2 of 3
next →
